Acta Crystallographica Section E

## Structure Reports

Online
ISSN 1600-5368

## Feng-Xia Sun,* Hua Zhao and Hong-Xia Du

College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, People's Republic of China

Correspondence e-mail: fxsun001@163.com

## Key indicators

Single-crystal X-ray study
$T=294 \mathrm{~K}$
Mean $\sigma(\mathrm{C}-\mathrm{C})=0.004 \AA$
Disorder in main residue
$R$ factor $=0.051$
$w R$ factor $=0.149$
Data-to-parameter ratio $=12.7$

For details of how these key indicators were automatically derived from the article, see http://journals.iucr.org/e.

[^0]
## Ethyl 5-carboxy-2,6-dimethyl-4-(4-nitro-phenyl)-1,4-dihydropyridine-3-carboxylate

The title compound, $\mathrm{C}_{17} \mathrm{H}_{18} \mathrm{~N}_{2} \mathrm{O}_{6}$, is an important intermediate in the synthesis of nefidipine analogs. The crystal packing is stabilized by intermolecular $\mathrm{N}-\mathrm{H} \cdots \mathrm{O}$ hydrogen bonds and $\mathrm{O}-\mathrm{H} \cdots \mathrm{O}$ hydrogen bonds.

## Comment

4-Aryl-1,4-dihydropyridine-3,5-dicarboxylic diesters of the nefidipine type have become almost indispensable for the treatment of cardiovascular diseases since they first appeared on the market in 1975 (Yiu \& Knaus, 1999; Goldmann \& Stoltefuss, 1991). The title compound, (I) (Fig. 1), is a key intermediate for the preparation of nefidipine analogs (Dagnino et al., 1987).


The dihydropyridine ring has a flattened boat conformation. This compares well with the structure of 3-benzotriazol-1-yl-5-ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5dicarboxylate and nefidipine (Sun et al., 2006; Hofmann \& Cimiraglia, 1990). Atoms C3 and N1 are displaced from the mean plane formed by the other atoms in the same ring by 0.389 (1) and 0.196 (1) $\AA$, respectively. The dihedral angle between the benzene ring and the $\mathrm{C} 1 / \mathrm{C} 2 / \mathrm{C} 4 / \mathrm{C} 5$ plane is $89.16^{\circ}$. The crystal packing is stabilized by intermolecular $\mathrm{N}-$ $\mathrm{H} \cdots \mathrm{O}$ hydrogen bonds and $\mathrm{O}-\mathrm{H} \cdots \mathrm{O}$ hydrogen bonds.

## Experimental

Diethyl 2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, (II), was prepared by a Hanstzch condensation reaction (Dagnino et al., 1987). The title compound, (I), was prepared by

Received 24 October 2006 Accepted 30 October 2006
hydrolysis of (II). Compound (II) ( 374 mg , 1 mmol ) was dissolved in ethanol $(10 \mathrm{ml}) . \mathrm{NaOH}(320 \mathrm{mg}, 5 \mathrm{mmol})$ in water $(2 \mathrm{ml})$ was added to the solution at room temperature. The reaction mixture was stirred under reflux for a further 8 h . The solvent was removed by vacuum evaporation. Water $(50 \mathrm{ml})$ was added and the solution was extracted with ethyl acetate. The organic layer contained the unreacted ester. The aqueous layer was acidified with hydrochloric acid to $\mathrm{pH} 3-4$. The target compound was extracted with ethyl acetate and purified by chromatography on a silica-gel column (eluted by ethyl acetate and petroleum, 1:5) at room temperature. The product was obtained in $50 \%$ yield. Suitable crystals were obtained by slow evaporation of an ethanol solution.

## Crystal data

| $\mathrm{C}_{17} \mathrm{H}_{18} \mathrm{~N}_{2} \mathrm{O}_{6}$ | $Z=4$ |
| :--- | :--- |
| $M_{r}=346.33$ | $D_{x}=1.343 \mathrm{Mg} \mathrm{m}^{-3}$ |
| Monoclinic, $P 2_{1} / n$ | $\mathrm{Mo} \mathrm{K} \mathrm{\alpha} \mathrm{radiation}$ |
| $a=10.323(2) \AA$ | $\mu=0.10 \mathrm{~mm}^{-1}$ |
| $b=15.590(3) \AA$ | $T=294(2) \mathrm{K}$ |
| $c=11.202(3) \AA$ | Block, yellow |
| $\beta=108.201(4)^{\circ}$ | $0.40 \times 0.28 \times 0.10 \mathrm{~mm}$ |
| $V=1712.7(7) \AA^{3}$ |  |
|  |  |
| Data collection |  |
| Bruker SMART CCD area-detector | 8538 measured reflections |
| $\quad$ diffractometer | 3024 independent reflections |
| $\varphi$ and $\omega$ scans | 1890 reflections with $I>2 \sigma(I)$ |
| Absorption correction: multi-scan | $R_{\text {int }}=0.036$ |
| $\quad(S A D A B S ;$ Sheldrick, 1996$)$ | $\theta_{\text {max }}=25.0^{\circ}$ |
| $T_{\text {min }}=0.960, T_{\text {max }}=0.990$ |  |

## Refinement

Refinement on $F^{2}$

$$
\begin{aligned}
& w=1 /\left[\sigma^{2}\left(F_{\mathrm{o}}^{2}\right)+(0.0635 P)^{2}\right. \\
& \quad+0.8733 P] \\
& \text { where } P=\left(F_{\mathrm{o}}^{2}+2 F_{\mathrm{c}}^{2}\right) / 3 \\
& (\Delta / \sigma)_{\max }=0.003 \\
& \Delta \rho_{\max }=0.25 \mathrm{e}^{-3} \\
& \Delta \rho_{\min }=-0.20 \mathrm{e}^{-3}
\end{aligned}
$$

$w R\left(F^{2}\right)=0.149$
$S=1.02$
3024 reflections
239 parameters
H -atom parameters constrained


Figure 1
The molecular structure of compound (I). Displacement ellipsoids are drawn at the $30 \%$ probability level and H atoms are shown as small spheres of arbitrary radius.

The bond angles were also restrained by restraining the $1-3$ atom distances.

Data collection: SMART (Bruker, 1997); cell refinement: SAINT (Bruker, 1997); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics: SHELXTL (Bruker, 1997); software used to prepare material for publication: SHELXTL.

The authors gratefully acknowledge the support from Hebei University of Science and Technology.

## References

Bruker (1997). SMART, SAINT and SHELXTL. Bruker AXS Inc., Madison, Wisconsin, USA.
Dagnino, L., Li, K. K., Wolowyk, M. W., Wynn, H. \& Triggle, C. R. (1987). J. Med. Chem. 30, 640-646.
Goldmann, S. \& Stoltefuss, J. (1991). Angew. Chem. Int. Ed. Engl. 30, 15591578.

Hofmann, H. J. \& Cimiraglia, R. (1990). J. Mol. Struct. (Theochem), 205, 1-11. Sheldrick, G. M. (1996). SADABS. University of Göttingen, Germany. Sheldrick, G. M. (1997). SHELXS97 and SHELXL97. University of Göttingen, Germany.
Sun, F.-X., Fu, D.-C. \& Yu, Y.-F. (2006). Acta Cryst. E62, o4207-o4208.
Yiu, S. H. \& Knaus, E. E. (1999). Drug Dev. Res. 48, 26-37.


[^0]:    (C) 2006 International Union of Crystallography All rights reserved

